MOLECULAR MODELING AND VIRTUAL SCREENING FOR COMPUTER-AIDED DESIGN OF HCV NS5B POLYMERASE INHIBITORS
Universal Journal of Pharmaceutical Research · 15.07.2026
DOI: 10.22270/ujpr.v11i3.1586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Universal Journal of Pharmaceutical Research, online erschienen am 15.07.2026. Verfasst von Bertrand-Ulrich Yavo und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims and objectives: This study aims to design new inhibitors for the Hepatitis C Virus (HCV) Non-Structural Protein 5B (NS5B) polymerase, an enzyme essential for viral replication. The research addresses an urgent public health issue affecting 71 million people and causing approximately 242,000 deaths annually. Methodology: The research follows a computer-aided rational design approach. A Quantitative Structure-Activity Relationship (QSAR) model was developed using 24 quinazolinone derivatives (QDs) to correlate Gibbs free energy with experimental inhibition constants. The bound conformations of the ligands were used to construct a 3D-QSAR pharmacophore (PH4) model. A virtual library of 168,750 QDs was generated and filtered using ADME (Absorption, Distribution, Metabolism, and Excretion) criteria and PH4 screening. Conformational stability was evaluated through 200-ns molecular dynamics (MD) simulations. Binding free energy variations were quantified using the Molecular Mechanics - Generalized Born Surface Area (MM-GBSA) approach on MD trajectories, calculating molecular mechanics energy, solvation energy, and surface area contributions under the OPLS2005 force field.
Results
The QSAR model showed high predictive power and the PH4 model achieved an R2 of 0.85. Screening identified 39 potent analogues. The lead candidate, 3-6-4-45, exhibited a predicted inhibitory concentration of 0.62 nM, approximately 96 times more active than the best reference ligand (60 nM). MD simulations confirmed stability with RMSD values between 1.5 and 3 Å. MM-GBSA binding energies converged with predicted complexation energies, validating the computational reliability.
Conclusion
The integration of molecular modeling and in silico screening successfully identified six potent candidate inhibitors of the HCV NS5B polymerase with favorable pharmacokinetic profiles. These analogues represent high-affinity candidates for future therapeutic development. Peer Review History: Received 5 April 2026; Reviewed 13 May 2026; Accepted 10 June; Available online 15 July 2026 Academic Editor: Dr. Iman Muhammad Higazy, National Research Center, Egypt, imane.higazy@hotmail.com Reviewers: Dr. Sarfaraz Ahmed, Global Institute of Pharmaceutical Education and Research, Kashipur, Uttarakhand, India, sarfarazahmed1@gmail.com Prof. Amani S. Awaad, Prince Sattam Bin Abdulaziz University, Al-Kharj. KSA., amaniawaad@hotmail.com
Zitieren
APA
Yavo, B., Esmel, A. E., Kouakou, K. J., Kéita, M., & Eugène, M. (2026). MOLECULAR MODELING AND VIRTUAL SCREENING FOR COMPUTER-AIDED DESIGN OF HCV NS5B POLYMERASE INHIBITORS. Universal Journal of Pharmaceutical Research. https://doi.org/10.22270/ujpr.v11i3.1586
Vancouver
Yavo B, Esmel AE, Kouakou KJ, Kéita M, Eugène M. MOLECULAR MODELING AND VIRTUAL SCREENING FOR COMPUTER-AIDED DESIGN OF HCV NS5B POLYMERASE INHIBITORS. Universal Journal of Pharmaceutical Research. 2026. doi:10.22270/ujpr.v11i3.1586
BibTeX
@article{Yavo2026,
author = {Yavo, Bertrand-Ulrich and Esmel, Akori Elvice and Kouakou, Kouakou Jean-Louis and Kéita, Melalie and Eugène, Megnassan},
title = {MOLECULAR MODELING AND VIRTUAL SCREENING FOR COMPUTER-AIDED DESIGN OF HCV NS5B POLYMERASE INHIBITORS},
journal = {Universal Journal of Pharmaceutical Research},
year = {2026},
doi = {10.22270/ujpr.v11i3.1586}
}
EUVIMED